Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20170529

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue

    Sponsor: ASCO

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201218 - Civantos Jr Francisco

  • Investigator:
    Francisco Civantos Jr
    RCname Email

    Coordinator:

    IRB: 20201218

    SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx

    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer - NRG-HN006

    Eligibility Criteria - NCT04333537 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200056 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    Coordinator:
    RCemailImg Nailet Real Bestard
    RCphone +1 (305) 2438173

    IRB: 20200056

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid

    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester

    Title:

    A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

    Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201539 - Franzmann Elizabeth

  • Investigator:
    Elizabeth Franzmann
    RCname Email

    Coordinator:
    RCemailImg Zaida Abreu
    RCphone +1 (305) 2434243

    IRB: 20201539

    SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx

    Sponsor: Aveta Biomics

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    An exploratory study to evaluate the safety and effectiveness of APG-157 as neo-adjuvant/Induction therapy for patients with head and neck squamous cell cancer (HNSCC) of the oral cavity

  • MATCH - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210067 - Ikpeazu Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    Coordinator:

    IRB: 20210067

    SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx

    Sponsor: ALX Oncology

    Enrolling Sites:

    Deerfield
    Plantation
    Sylvester

    Title:

    A Phase 2 Study of ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

    Eligibility Criteria - NCT04675333 *This information has been extracted from " www.clinicaltrials.gov"

  • VERSATILE - Krill Jackson, Elisa

  • Investigator:
    Elisa Krill Jackson
    RCname Email

    Coordinator:
    RCemailImg Donald Cantrell II
    RCphone +1 (305) 2435006 x6-5006

    IRB: 20200726

    SDG: Head and Neck Cancer
    Disease Site(s):

    Larynx,Lip, Oral Cavity and Pharynx

    Sponsor: PDS Biotechnology

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK-RDOTAP/HPV-16 E6 & E7 peptides) and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy as a First Line Treatment in Subjects with Recurrent and/or Metastatic Head and Neck Cancer and High-risk Human Papillomavirus-16 (HPV16) Infection.

    Eligibility Criteria - NCT04260126 *This information has been extracted from " www.clinicaltrials.gov"

  • PRO-ACTIVE - Landera, Mario

  • Investigator:
    Mario Landera
    RCname Email

    Coordinator:

    IRB: 20190863

    SDG: Head and Neck Cancer
    Disease Site(s):

    Larynx,Lip, Oral Cavity and Pharynx

    Sponsor: PCORI

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH

    Title:

    PRO-ACTIVE: Comparing The Effectiveness of Prophylactic Swallow Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer

    Eligibility Criteria - NCT03455608 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210501 - Lundy Donna

  • Investigator:
    Donna Lundy
    RCname Email

    Coordinator:

    IRB: 20210501

    SDG: Head and Neck Cancer
    Disease Site(s):

    Larynx

    Sponsor: SCCC

    Enrolling Sites:

    Sylvester

    Title:

    Evaluation of a Disposable Hands-Free Heat and Moisture Exchanger (HME) valve: The Blom-Singer® SpeakFree? HME Hands Free Valve

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20180279

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder,Bones and Joints,Cervix Uteri,Colon,Corpus Uteri,Kidney,Lip, Oral Cavity and Pharynx,Lung,Lymphoid Leukemia,Non-Hodgkin Lymphoma,Pancreas,Prostate,Rectum,Soft Tissue

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • RTX-240-01 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone +1 (305) 2435486

    IRB: 20200686

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Multiple

    Sponsor: Rubius Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    PHASE 1/2 STUDY OF RTX-240 AS A MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB

    Eligibility Criteria - NCT04372706 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210783 - Nicolli Elizabeth

  • Investigator:
    Elizabeth Nicolli
    RCname Email

    Coordinator:

    IRB: 20210783

    SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx

    Sponsor: ECOG

    Enrolling Sites:

    Sylvester

    Title:

    A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features

    Eligibility Criteria - NCT04671667 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191009 - Pimentel Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    Coordinator:

    IRB: 20191009

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Bones and Joints,Lip, Oral Cavity and Pharynx

    Sponsor: HOOKIPA PHARMA

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I/II Study of TheraT® Vector(s) Expressing HumanPapillomavirus 16 Positive (HPV 16+) Specific Antigens inPatients with HPV 16+ Confirmed Cancers

    Eligibility Criteria - NCT04180215 *This information has been extracted from " www.clinicaltrials.gov"

  • Tbio-6517-ITu-001 - Pimentel, Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20200277

    SDG: Colorectal Cancer
    Disease Site(s):

    Multiple

    Sponsor: TSB

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors

    Eligibility Criteria - NCT04301011 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-095 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:

    IRB: 20160656

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Anus,Lip, Oral Cavity and Pharynx,Lung,Other Hematopoietic

    Sponsor: AMC

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors

    Eligibility Criteria - NCT02408861 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191010 - Samuels Stuart

  • Investigator:
    Stuart Samuels
    RCname Email

    Coordinator:

    IRB: 20191010

    SDG: Head and Neck Cancer
    Disease Site(s):

    Other Skin

    Sponsor: MERCK SHARP & DOHME

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma(LA cSCC) (KEYNOTE-630).

    Eligibility Criteria - NCT03833167 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191016 - Samuels Stuart

  • Investigator:
    Stuart Samuels
    RCname Email

    Coordinator:
    RCemailImg Lilly Sanchez
    RCphone +1 (305) 2430974

    IRB: 20191016

    SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx

    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer

    Eligibility Criteria - NCT03952585 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210033 - Samuels Stuart

  • Investigator:
    Stuart Samuels
    RCname Email

    Coordinator:

    IRB: 20210033

    SDG: Head and Neck Cancer
    Disease Site(s):

    Larynx,Lip, Oral Cavity and Pharynx

    Sponsor: NRG

    Enrolling Sites:

    Sylvester

    Title:

    Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

    Eligibility Criteria - NCT04533750 *This information has been extracted from " www.clinicaltrials.gov"

  • EA3163 - Sargi, Zoukaa

  • Investigator:
    Zoukaa Sargi
    RCname Email

    Coordinator:
    RCemailImg Lilly Sanchez
    RCphone +1 (305) 2430974

    IRB: 20180505

    SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx

    Sponsor: ECOG

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    EA3163:Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC)

    Eligibility Criteria - NCT03493425 *This information has been extracted from " www.clinicaltrials.gov"